Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Baker Bros Advisors Increases Stake in Seattle Genetics Inc (SGEN)

Julian Baker and Felix Baker are betting big on Seattle Genetics, Inc. (NASDAQ:SGEN). In a recent Form 4 filing with the Securities and Exchange Commission, their fund, Baker Bros. Advisors, has revealed the addition of more than 1 million shares in 26 transactions at prices varying between $42.31 and $44.04 per share. As a result the fund has amassed 20,493,349 shares.

Seattle Genetics, Inc. (NASDAQ:SGEN)

Other hedge fund managers are not that bullish about Seattle Genetics, Inc. (NASDAQ:SGEN). Jim Simons of Renaissance Technologies has been reducing his fund’s exposure to the stock. During the third quarter of 2013, Renaissance reduced its position by 16% and reported ownership of 339,213 shares valued at $14.8 million in their latest 13F report. Israel Englander has trimmed his fund’s exposure by 5% in Q3 and Millennium Management now holds 156,350 shares worth approximately $6.8 million. D. E. Shaw has more than halved his fund’s stake in Seattle Genetics, leaving his fund, D E Shaw, with 226,816 shares reportedly worth $9.9 million.

Seattle Genetics, Inc. (NASDAQ:SGEN) stock has been in an uptrend most of 2013, surging 86% to a current price of $45 per share. The company has a market cap of $5.4 billion and does not pay a dividend. The stock has a beta of 1.15, meaning it does not deviate too much from the market.

For the three months ended September 30, 2013, the company reported revenues of $36.5 million, slightly below the figure reported for the same period in 2012, and a loss of $0.19 per share. For the current quarter, analysts expect Seattle Genetics to report revenues of $59 million and a loss per share of $0.24.

Disclosure: none

Recommended reading:

Mario Gabelli, GAMCO’s Activist Moves In Superior Industries International Inc. (SUP), Griffin Land & Nurseries, Inc. (GRIF) & Telephone & Data Systems, Inc. (TDS)

Latest Hedge Fund Moves: Carl Icahn, Ken Griffin, Steven Cohen and Others

Ken Griffin, Citadel Also Disclose Boosting Their Holding in Taylor Morrison Home Corp (TMHC)

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.